title: De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
abstract: De novo CD5+ diffuse large B-cell lymphoma (CD5+ DLBCL) is known to have phenotypically and genotypically different characteristics than CD5- DLBCL and mantle cell lymphoma (MCL). To further characterize CD5+ DLBCL, 109 patients with CD5+ DLBCL were reviewed, and the results were compared with those of 384 CD5- DLBCL and 128 cyclin D1+ MCL patients. Patients with CD5+ DLBCL showed a higher age distribution (median, 66 years; P =.0083) and a female predominance (male-female ratio, 49:60, P =.011) compared with those with CD5- DLBCL. CD5+ DLBCL was more closely associated with many aggressive clinical features or parameters than CD5- DLBCL: 69% older than 60 years (P =.039), 34% with performance status greater than 1 (P =.0016), 69% with serum lactate dehydrogenase level higher than normal (P <.0001), 62% with stage III/IV disease at diagnosis (P =.0023), 35% with more than one extranodal site (P =.023), and 40% with B symptoms (P =.0031). The overall International Prognostic Index score was thus significantly higher for the patients with CD5+ DLBCL than for those with CD5- DLBCL (P =.00005). The most frequent site of extranodal involvement was bone marrow (28%), a higher frequency than that for CD5- DLBCL (P <.0001) but lower than that for cyclin D1+ MCL (P =.0015). Histopathologically, CD5+ DLBCL showed centroblastic morphology except for 3 patients with immunoblastic disease, and interfollicular growth pattern (7%) and intravascular or intrasinusoidal infiltration (19%) were observed. Immunophenotypically, CD5+ DLBCL was characterized by a CD5+CD10-CD19+CD20+CD21-CD23- cyclin D1- phenotype and a predominance of surface IgMkappa. Of particular interest is that CD5+ DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5- DLBCL (P =.0026). These findings suggest that CD5+ DLBCL may constitute a unique subgroup of DLBCL.
authors.affiliation: Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan.
authors.forename: Motoko
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Masao
authors.initials: M
authors.lastname: Seto
authors.forename: Masataka
authors.initials: M
authors.lastname: Okamoto
authors.forename: Ryo
authors.initials: R
authors.lastname: Ichinohasama
authors.forename: Naoya
authors.initials: N
authors.lastname: Nakamura
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshino
authors.forename: Junji
authors.initials: J
authors.lastname: Suzumiya
authors.forename: Takuhei
authors.initials: T
authors.lastname: Murase
authors.forename: Ikuo
authors.initials: I
authors.lastname: Miura
authors.forename: Takashi
authors.initials: T
authors.lastname: Akasaka
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Tamaru
authors.forename: Ritsuro
authors.initials: R
authors.lastname: Suzuki
authors.forename: Yoshitoyo
authors.initials: Y
authors.lastname: Kagami
authors.forename: Masami
authors.initials: M
authors.lastname: Hirano
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiku
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018956:CD5 Antigens / Q000032:analysis*; D019938:Cyclin D1 / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D018956:CD5 Antigens; D019938:Cyclin D1